AXL and renal cell adenocarcinoma: In this study, we evaluated the effects of two different AXL inhibitors, a small molecule bemcentinib (BGB324, BerGenBio) and a newly developed humanized anti‐AXL antibody tilvestamab (BGB149, BerGenBio) (Blø et al., 2020) alone or in combination with multi‐targeted tyrosine kinase inhibitor (Sunitinib, Pfizer) in an orthotopic RCC model.